Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

Blood (2024) 144 (Supplement 1): 679.

https://doi.org/10.1182/blood-2024-211959

Published: 2024

Journal Articles

Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection

Snegha Ananth, Yi-Jiun Su, Mark P. Hamilton, Neha Agarwal, Wen-Kai Weng, Saurabh Dahiya, Sushma Bharadwaj, Jayasindhu Mallampet, Melody Smith, Katherine Ann Kong, Abigail Twoy, David B. Miklos, Matthew J. Frank

Blood (2023) 142 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2023-188338

Published: 2023

Journal Articles

Differences in Characteristics and Outcomes of Central Nervous System Versus Systemic Relapse after First Line Therapy in DLBCL Patients: A Veterans Health Administration (VHA) Study

Blood (2023) 142 (Supplement 1): 5161.

https://doi.org/10.1182/blood-2023-190641

Published: 2023

Journal Articles

Real-World Applications of Guideline Based Diagnostic and Treatment Patterns for Diffuse Large B-Cell Lymphoma within the Veterans Health Administration (VHA)

Blood (2023) 142 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2023-187709

Published: 2023

Journal Articles

Retrospective Analysis of Treatment Patterns and Outcomes in Geriatric Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Veterans Health Administration (VHA)

Blood (2023) 142 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2023-190571

Published: 2023

Journal Articles

Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Blood (2023) 142 (Supplement 1): 2125.

https://doi.org/10.1182/blood-2023-187617

Published: 2023

Journal Articles

Survival Outcomes of Diffuse Large B Cell Lymphoma Beyond the Rituximab Era: Comprehensive Analysis of a Veteran Population within the Veterans Health Administration over 11 Years

Blood (2023) 142 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2023-190048

Published: 2023

Journal Articles

Examining Racial Disparities in Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Blood (2023) 142 (Supplement 1): 2398.

https://doi.org/10.1182/blood-2023-184997

Published: 2023

Journal Articles

Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 5195–5197.

https://doi.org/10.1182/blood-2022-171126

Published: 2022

Journal Articles

Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Blood (2022) 140 (Supplement 1): 9561–9563.

https://doi.org/10.1182/blood-2022-170661

Published: 2022

Journal Articles

The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration

Blood (2022) 140 (Supplement 1): 2061–2062.

https://doi.org/10.1182/blood-2022-170576

Published: 2022

Journal Articles

Ethnicity, Nativity and Outcomes in Burkitt Lymphoma Among US Hispanics: Texas and Florida State Database Study

Snegha Ananth, Ysaith Efren Orellana, Joel E Michalek, Qianqian Liu, Adolfo Enrique Diaz Duque

Blood (2021) 138 (Supplement 1): 4087.

https://doi.org/10.1182/blood-2021-149981

Published: 2021

Journal Articles

Characteristics of Patients with Central Nervous System Relapse in Veterans with Diffuse Large B-Cell Lymphoma within the Veterans Health Administration

Amy M Horowitz, Madison H. Williams, Ryan A. Williams, Jean Pierre Blaize, Snegha Ananth, Michael M. Song, Brian Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Ricardo Espinoza-Gutarra, Juan J. Toro, Lindsey Lu, Kana Tai Lucero, Jennifer Whitehead, Kathleen Franklin, Michael Mader, Zohra Nooruddin

Blood (2021) 138 (Supplement 1): 2501.

https://doi.org/10.1182/blood-2021-147958

Published: 2021

Journal Articles

A Retrospective Study of Hospice Enrollment in Patients with Diffuse Large B Cell Lymphoma within the Veterans Health Administration

Kana Tai Lucero, Madison H. Williams, Ryan A. Williams, Snegha Ananth, Jean Pierre Blaize, Michael M. Song, Brian Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Ricardo Espinoza-Gutarra, Juan J. Toro, Lindsey Lu, Jennifer Whitehead, Kathleen Franklin, Michael Mader, Zohra Nooruddin

Blood (2021) 138 (Supplement 1): 2517.

https://doi.org/10.1182/blood-2021-153278

Published: 2021

Journal Articles

Impact of Age on Treatment and Outcome in Newly Diagnosed DLBCL (Diffuse Large B-cell Lymphoma) Patients in the United States Veteran Population (2011-2017)

Snegha Ananth, MBBS, Madison H. Williams, MD, Ryan A. Williams, MD, Jean Pierre Blaize, MD, David Gregorio, DO, Michael M. Song, MDPhDPharmD, Gerardo Manuel Rosas, MD, Lakene Raissa Djoufack Djoumessi, MD, Brian Warnecke, DO, Abhishek Pandya, DO, Vivian Dee, NP, Michael Mader, MS, Juan J. Toro, MD MS, Kathleen Franklin, Phillip Nazarewicz, Zohra Nooruddin, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143206

Published: 2020

Journal Articles

Impact of Differences in Time from Diagnosis to Treatment on DLBCL Response and Survival Outcomes: A VA Study

Ryan A. Williams, MD, Madison H. Williams, MD, Jean Pierre Blaize, MD, Snegha Ananth, MBBS, David Gregorio, DO, Gerardo Manuel Rosas, MD, Michael M. Song, MDPhDPharmD, Brian Warnecke, DO, Abhishek Pandya, DO, Lakene Raissa Djoufack Djoumessi, MD, Vivian Dee, NP, Phillip Nazarewicz, Juan J. Toro, MD MS, Kathleen Franklin, Michael Mader, MS, Zohra Nooruddin, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-143215

Published: 2020

Journal Articles

Does Hispanic Origin Affect the Repartition and Outcome of Marginal Zone Lymphoma?

Lakene Raissa Djoufack Djoumessi, MD, Snegha Ananth, MBBS, Michael E Auster, DO, Joel E Michalek, PhD, Qianqian Liu, PhD, Adolfo Enrique Diaz Duque, MDMSc

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-136220

Published: 2020

Journal Articles

The Impact of Race and Ethnicity on Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Madison H. Williams, MD, Ryan A. Williams, MD, Jean Pierre Blaize, MD, Snegha Ananth, MBBS, David Gregorio, DO, Gerardo Manuel Rosas, MD, Michael M. Song, MDPhDPharmD, Brian Warnecke, DO, Abhishek Pandya, DO, Lakene Raissa Djoufack Djoumessi, MD, Vivian Dee, NP, Phillip Nazarewicz, Kathleen Franklin, Juan J. Toro, MD MS, Michael Mader, MS, Zohra Nooruddin, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142118

Published: 2020

Journal Articles

Demographic Differences in the Treatment and Mortality of Lymphoplasmacytic Lymphoma in Texas: Does Ethnicity Play Any Role?

Michael E Auster, DO, Snegha Ananth, MBBS, Lakene Raissa Djoufack Djoumessi, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz Duque, MDMSc

Blood (2020) 136 (Supplement 1): 17–20.

https://doi.org/10.1182/blood-2020-138604

Published: 2020

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

NARROW

Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection

Differences in Characteristics and Outcomes of Central Nervous System Versus Systemic Relapse after First Line Therapy in DLBCL Patients: A Veterans Health Administration (VHA) Study

Real-World Applications of Guideline Based Diagnostic and Treatment Patterns for Diffuse Large B-Cell Lymphoma within the Veterans Health Administration (VHA)

Retrospective Analysis of Treatment Patterns and Outcomes in Geriatric Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Veterans Health Administration (VHA)

Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Survival Outcomes of Diffuse Large B Cell Lymphoma Beyond the Rituximab Era: Comprehensive Analysis of a Veteran Population within the Veterans Health Administration over 11 Years

Examining Racial Disparities in Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma

Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration

Ethnicity, Nativity and Outcomes in Burkitt Lymphoma Among US Hispanics: Texas and Florida State Database Study

Characteristics of Patients with Central Nervous System Relapse in Veterans with Diffuse Large B-Cell Lymphoma within the Veterans Health Administration

A Retrospective Study of Hospice Enrollment in Patients with Diffuse Large B Cell Lymphoma within the Veterans Health Administration

Impact of Age on Treatment and Outcome in Newly Diagnosed DLBCL (Diffuse Large B-cell Lymphoma) Patients in the United States Veteran Population (2011-2017)

Impact of Differences in Time from Diagnosis to Treatment on DLBCL Response and Survival Outcomes: A VA Study

Does Hispanic Origin Affect the Repartition and Outcome of Marginal Zone Lymphoma?

The Impact of Race and Ethnicity on Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Demographic Differences in the Treatment and Mortality of Lymphoplasmacytic Lymphoma in Texas: Does Ethnicity Play Any Role?

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only